Clinical characteristics of patients in the study group
| Diagnosis . | Number . | Median age (range) . | Male gender . |
|---|---|---|---|
| Low risk | 64 | 45 (19-60) | 33 |
| ALL CR1 | 5 | 33 (30-51) | 2 |
| AML CR1 | 16 | 46 (19-60) | 10 |
| CML CP1 | 37 | 45 (21-58) | 19 |
| MDS RA, RARS | 6 | 45 (21-58) | 2 |
| High risk | 49 | 42 (22-64) | 36 |
| ALL not CR1 | 3 | 25 (24-64) | 3 |
| AML not CR1 | 12 | 50 (34-62) | 8 |
| CLL | 2 | 46 (45-46) | 2 |
| CML not CP1 | 3 | 33 (24-36) | 3 |
| HD | 5 | 29 (24-35) | 3 |
| NHL | 12 | 40 (22-57) | 8 |
| MDS not RA, RARS | 10 | 45 (39-53) | 8 |
| MM | 2 | 50 (49-51) | 1 |
| Diagnosis . | Number . | Median age (range) . | Male gender . |
|---|---|---|---|
| Low risk | 64 | 45 (19-60) | 33 |
| ALL CR1 | 5 | 33 (30-51) | 2 |
| AML CR1 | 16 | 46 (19-60) | 10 |
| CML CP1 | 37 | 45 (21-58) | 19 |
| MDS RA, RARS | 6 | 45 (21-58) | 2 |
| High risk | 49 | 42 (22-64) | 36 |
| ALL not CR1 | 3 | 25 (24-64) | 3 |
| AML not CR1 | 12 | 50 (34-62) | 8 |
| CLL | 2 | 46 (45-46) | 2 |
| CML not CP1 | 3 | 33 (24-36) | 3 |
| HD | 5 | 29 (24-35) | 3 |
| NHL | 12 | 40 (22-57) | 8 |
| MDS not RA, RARS | 10 | 45 (39-53) | 8 |
| MM | 2 | 50 (49-51) | 1 |